A Year of Growth, Research, Discovery and Life-Saving Therapies 

​​​

As we transition from winter into spring, we continue the year with unwavering commitment to expanding research and building new partnerships. With the arrival of spring just days away, I would like to share some recent news and updates.

​

We began the New Year with a focus on developing more therapies and fostering growth, and fittingly, the theme of my first engagement this year was "AI (Artificial Intelligence) for Growth."​   I was honored to be invited to an event in Paris on February 6th to participate in a thematic workshop as part of the exclusive "AI for Growth – Fostering UK-France Collaboration" event. Held at the residence of the British Ambassador to France, Her Excellency Dame Menna Rawlings, the event brought together companies from the UK and France to discuss harnessing artificial intelligence within the life sciences. I participated in the Life Sciences Round table and workshop, and attended the follow-up reception. This event served as a reminder of the crucial work we are doing, utilizing the power of Artificial Intelligence and machine learning combined with our therapeutic and diagnostic platforms to design and develop life-saving therapies.

​

I am thrilled to share more exciting news from earlier this quarter. In January, Dr. Mark Treherne, PhD joined our Science Advisory Board.  Dr. Treherne is a distinguished biopharmaceutical executive and has over 30 years of pharma experience in the discovery and diagnosis of novel treatments for diseases with complex and unmet medical needs. He originally trained as a neuroscientist with a PhD in Pharmacology from Cambridge University and was formerly at Pfizer, where he was responsible for research into neurodegenerative diseases in the UK. He then set up Cambridge Drug Discovery as a co-founder and Chief Executive in 1997, which was subsequently sold to a public company on the London Stock Exchange in 2001. We are excited to welcome Mark to our team as he brings extensive leadership and R&D experience to our team further strengthening our work towards taking more programs to the clinic and patients.   

​

I am also pleased to share the news of our co-founder and inventor of our Peptide Therapeutic Platforms, Professor Moein Moghimi’s recent publication of an opinion paper in Nature Reviews Bioengineering. The paper provides valuable insights into the interactions between lipoproteins and nanomedicine, an area of research in which Professor Moghimi has made significant contributions, particularly regarding the interactions of biological factors with nanomedicines.  Professor Moghimi highlights "Nanomedicines interact with lipoproteins in the blood, which might result in alterations in both nanomedicine and lipoprotein structure and function. Such interactions could also be exploited for site-specific delivery through a ‘lipoprotein Trojan Horse’ mechanism and to restore dysfunctional lipoproteins."  Furthermore, in this paper Professor Moghimi discusses the role of lipoproteins, such as LDL, in delivering nucleic acids from intravenously injected serum-unstable nucleic acid-lipid nanoparticle therapeutics, like Onpattro. He proposes a mechanism where "forced sieving" of Onpattro by erythrocytes and leukocytes in the liver could lead to siRNA release, which then binds to LDL and facilitates delivery to hepatocytes.  We congratulate Professor Moghimi on this noteworthy opinion paper and continuation of a line of research which has been quite significantly explored in his laboratory.  

​

Over the past few months, I've been traveling across Europe connecting with our current collaborators and forge new partnerships. As always, our focus remains on bringing life-saving therapies to patients. Every milestone we reach highlights the impact of innovation and teamwork. We believe in the power of partnerships. So, please do not hesitate to reach out if you would like to learn more about our platforms and/or meet with our team at any of the upcoming events or conferences. In the coming months we will be at several conferences: Bio Intergate, in Cambridge, UK (May 2025), Oxford Global conference in Basel, Switzerland (June 2025), and 9th Nano Today conference in Singapore (September 2025). 

 

Keep in touch.

​

Shadi 

​

Winter 2025

​

​

Moghimi, S.M., Simberg, D. Nanomedicine–lipoprotein interactions. Nat Rev Bioeng (2025).

https://doi.org/10.1038/s44222-025-00291-9

​

​

​